The Chemours Company CC reported a net loss of $274 million or a loss of $1.81 per share for the second quarter of 2026. This compares favorably with the year-ago quarter’s net loss of $380 million or a loss of $2.53 per share.
Barring one-time items, earnings were 42 cents per share, which missed the Zacks Consensus Estimate of 43 cents by roughly 2.3%. Adjusted earnings also declined from 61 cents per share in the year-ago quarter.
The company reported second-quarter net sales of $1,591 million, reflecting a 1% decrease from the previous-year quarter. The figure missed the Zacks Consensus Estimate of $1,674.1 million by roughly 5%. Net sales were affected by a 4% decrease in volumes, partly offset by a 2% increase in price and a 1% favorable currency impact.
Adjusted EBITDA declined 5% year over year to $247 million for the quarter from $260 million. The decrease was due to higher costs in Advanced Performance Materials (APM) associated with the Washington Works outage and lower sales following the SPS Capstone line closure, partly offset by pricing increases across all segments.
The Chemours Company Price, Consensus and EPS Surprise
The Chemours Company price-consensus-eps-surprise-chart | The Chemours Company Quote
CC’s Segment Highlights
The Titanium Technologies (TT) division recorded revenues of $661 million in the second quarter, marking a 1% increase from the previous year. The figure missed our estimate of $663.6 million. The year-over-year increase was driven by a 2% rise in global pricing and a 1% currency tailwind, which more than offset a 2% decline in global volumes.
In the Thermal & Specialized Solutions (TSS) segment, revenues decreased 1% year over year to $591 million in the reported quarter. The figure missed our estimate of $637.3 million. The decline was due to a 4% fall in volumes, partly offset by a 2% increase in price and a slight currency tailwind. Lower volumes primarily reflected weaker North American stationary AC aftermarket sales of Opteon blends compared with elevated demand in the prior-year quarter.
TSS adjusted EBITDA increased 3% year over year to $213 million, while adjusted EBITDA margin improved one percentage point to 36%, aided by higher pricing and the timing of certain costs.
Revenues in the APM unit amounted to $326 million, which declined 6% year over year. The figure missed our estimate of $338.2 million. The downside was mainly caused by a 9% decrease in volumes, partly offset by a 2% increase in price and a slight currency tailwind. The volume decline primarily reflected the SPS Capstone line closure, while Performance Solutions sales rose 8% year over year on strength in data center and semiconductor end markets.
CC’s Financials
Operating cash flow in the second quarter was $158 million compared with $93 million in the year-ago quarter. Capital expenditures were $44 million compared with $43 million in the prior-year quarter. Free cash flow increased to $114 million from $50 million a year earlier.
As of June 30, 2026, Chemours had consolidated gross debt of $3.9 billion. Debt, net of $671 million in unrestricted cash and cash equivalents, was $3.2 billion. Total liquidity was $1.6 billion, and the net leverage ratio was approximately 4.4.
CC’s Outlook
For the third quarter, the company expects consolidated net sales to decline in the range of 5% to flat sequentially. Consolidated adjusted EBITDA is expected to be in the range of $175-$205 million. Corporate expenses are expected to be $40-$45 million. The company also expects capital expenditures of around $65 million and free cash flow of at least $50 million.
Chemours expects TSS’ net sales to decrease sequentially in the mid-teens to 20% range in the third quarter, reflecting less favorable seasonality and weaker Opteon blends aftermarket demand. Adjusted EBITDA is projected to be between $125 million and $140 million.
TT’s net sales are expected to increase sequentially in the low-to-mid-single-digit percentage range, driven by recent pricing announcements, with stable volumes. Adjusted EBITDA is expected to be in the range of $70-$80 million.
APM’s net sales are expected to increase sequentially in the mid-to-high-single-digit percentage range, driven by normalized operations at Washington Works and continued strength in Performance Solutions. Adjusted EBITDA for APM is expected to be between $20 million and $30 million.
For 2026, Chemours expects net sales to grow in the range of 1-5% year over year and adjusted EBITDA of $775-$825 million. Capital expenditures are expected in the range of $250-$280 million, with free cash flow conversion above 25%. The company continues to target a net leverage ratio of around 3.8x by year-end 2026.
CC’s Price Performance
Chemours’ shares have gained 17.4% in the past year compared with the 6.8% rise of the industry.
CC’s Zacks Rank & Key Picks
CC currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks are Almonty Industries Inc. ALM, ClearSign Technologies Corporation CLIR and Applied Industrial Technologies, Inc. AIT.
Almonty is expected to report second-quarter results on Aug. 13. The Zacks Consensus Estimate for ALM’s second-quarter earnings is pegged at 10 cents per share. It carries a Zacks Rank #2 (Buy) at present.
ClearSign is scheduled to report second-quarter 2026 results on Aug. 19. The consensus estimate for CLIR’s loss per share is pegged at 25 cents. CLIR presently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Applied Industrial is scheduled to report fourth-quarter fiscal 2026 results on Aug. 13. The Zacks Consensus Estimate for AIT’s fourth-quarter earnings per share is pegged at $2.92. AIT carries a Zacks Rank #2 at present.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>The Chemours Company (CC) : Free Stock Analysis Report
Applied Industrial Technologies, Inc. (AIT) : Free Stock Analysis Report
ClearSign Technologies Corporation (CLIR) : Free Stock Analysis Report
Almonty Industries Inc. (ALM) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.